237 related articles for article (PubMed ID: 28153094)
21. [Hepatogenic diabetes--the current concepts of its pathophysiology and therapy].
Siegel EG; Gallwitz B; Schmidt WE; Fölsch UR
Dtsch Med Wochenschr; 1999 Dec; 124(50):1530-5. PubMed ID: 10633781
[No Abstract] [Full Text] [Related]
22. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
23. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
[TBL] [Abstract][Full Text] [Related]
25. Engineering living therapeutics with synthetic biology.
Cubillos-Ruiz A; Guo T; Sokolovska A; Miller PF; Collins JJ; Lu TK; Lora JM
Nat Rev Drug Discov; 2021 Dec; 20(12):941-960. PubMed ID: 34616030
[TBL] [Abstract][Full Text] [Related]
26. [Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2 diabetes mellitus].
Kim MG; Choi WC
Korean J Hepatol; 2006 Dec; 12(4):524-9. PubMed ID: 17237630
[TBL] [Abstract][Full Text] [Related]
27. Lipid-lowering effects of oleanolic acid in hyperlipidemic patients.
Luo HQ; Shen J; Chen CP; Ma X; Lin C; Ouyang Q; Xuan CX; Liu J; Sun HB; Liu J
Chin J Nat Med; 2018 May; 16(5):339-346. PubMed ID: 29860994
[TBL] [Abstract][Full Text] [Related]
28. Antidiabetic effect of oleanolic acid: a promising use of a traditional pharmacological agent.
Wang X; Li YL; Wu H; Liu JZ; Hu JX; Liao N; Peng J; Cao PP; Liang X; Hai CX
Phytother Res; 2011 Jul; 25(7):1031-40. PubMed ID: 21254272
[TBL] [Abstract][Full Text] [Related]
29. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
30. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
31. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
32. Synthetic biology-inspired therapies for metabolic diseases.
Teixeira AP; Fussenegger M
Curr Opin Biotechnol; 2017 Oct; 47():59-66. PubMed ID: 28662442
[TBL] [Abstract][Full Text] [Related]
33. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
34. Synthetic mammalian gene circuits for biomedical applications.
Ye H; Aubel D; Fussenegger M
Curr Opin Chem Biol; 2013 Dec; 17(6):910-7. PubMed ID: 24466575
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
36. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
[TBL] [Abstract][Full Text] [Related]
37. Optogenetic therapeutic cell implants.
Ausländer D; Fussenegger M
Gastroenterology; 2012 Aug; 143(2):301-6. PubMed ID: 22721803
[No Abstract] [Full Text] [Related]
38. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.
De León DD; Crutchlow MF; Ham JY; Stoffers DA
Int J Biochem Cell Biol; 2006; 38(5-6):845-59. PubMed ID: 16202636
[TBL] [Abstract][Full Text] [Related]
39. Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.
Hartman I; Rojas E; Rodríguez-Molina D
Am J Ther; 2013; 20(4):384-93. PubMed ID: 23459193
[TBL] [Abstract][Full Text] [Related]
40. The molecular mechanisms underpinning the therapeutic properties of oleanolic acid, its isomer and derivatives for type 2 diabetes and associated complications.
Camer D; Yu Y; Szabo A; Huang XF
Mol Nutr Food Res; 2014 Aug; 58(8):1750-9. PubMed ID: 24740831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
